David L Chan1,2, Diego Ferone3, Manuela Albertelli3, Nick Pavlakis4, Eva Segelov5, Simron Singh6. 1. Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 2. Sydney Medical School, University of Sydney, Camperdown, NSW, Australia. 3. Endocrinology, Department of Internal Medicine and Medical Specialties, IRCCS AOU San Martino-IST, Center of Excellence for Biomedical Research, University of Genova, Genova, Italy. 4. Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia. 5. Medical Oncology, Monash Health and Monash University, Caulfield East, VIC, Australia. 6. Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. simron.singh@sunnybrook.ca.
Abstract
BACKGROUND/ PURPOSE: Somatostatin analogues are the cornerstone of systemic therapy for metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours for both hormonal control and antiproliferative effect. Dose escalation of somatostatin analogues is often utilized in clinical practice, but small studies have yielded mixed results. The aim of this study was to systematically determine the efficacy and safety of escalated-dose somatostatin analogues in the above setting. METHODS: Eligible trials (using more than 30 mg octreotide or 120 mg lanreotide/28 days) were identified from MEDLINE, EMBASE, other databases and conference proceedings. Demographics, disease control rate, objective response rate, biochemical response, improvement in symptoms and toxicity were abstracted. Trials were synthesized qualitatively. RESULTS: Eighteen studies (1002 patients) were identified. The risk of bias was moderate for objective response outcomes, but high for the outcomes of symptom control and toxicity due to open-label trial designs. Disease control rates ranged from 30 to 100%, but response rates were modest (at 0-14%). Rates of biochemical improvement (27-100%) and symptom improvement (23-100%) ranged widely depending on the population studied and the definition of response. The most common toxicities were fatigue, diarrhoea, abdominal discomfort and cholelithiasis, with no severe or unexpected toxicities compared to standard-dose somatostatin analogues. CONCLUSIONS: The current evidence indicates that escalated-dose somatostatin analogues are well-tolerated in patients with gastroenteropancreatic neuroendocrine tumours, with significant rates of disease control but low rates of tumour response. It was difficult to judge the exact rate of biochemical response or symptomatic improvement. There is a need for large, prospective studies investigating the role of escalated-dose somatostatin analogues in the treatment of metastatic gastroenteropancreatic neuroendocrine tumours.
BACKGROUND/ PURPOSE: Somatostatin analogues are the cornerstone of systemic therapy for metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours for both hormonal control and antiproliferative effect. Dose escalation of somatostatin analogues is often utilized in clinical practice, but small studies have yielded mixed results. The aim of this study was to systematically determine the efficacy and safety of escalated-dose somatostatin analogues in the above setting. METHODS: Eligible trials (using more than 30 mg octreotide or 120 mg lanreotide/28 days) were identified from MEDLINE, EMBASE, other databases and conference proceedings. Demographics, disease control rate, objective response rate, biochemical response, improvement in symptoms and toxicity were abstracted. Trials were synthesized qualitatively. RESULTS: Eighteen studies (1002 patients) were identified. The risk of bias was moderate for objective response outcomes, but high for the outcomes of symptom control and toxicity due to open-label trial designs. Disease control rates ranged from 30 to 100%, but response rates were modest (at 0-14%). Rates of biochemical improvement (27-100%) and symptom improvement (23-100%) ranged widely depending on the population studied and the definition of response. The most common toxicities were fatigue, diarrhoea, abdominal discomfort and cholelithiasis, with no severe or unexpected toxicities compared to standard-dose somatostatin analogues. CONCLUSIONS: The current evidence indicates that escalated-dose somatostatin analogues are well-tolerated in patients with gastroenteropancreatic neuroendocrine tumours, with significant rates of disease control but low rates of tumour response. It was difficult to judge the exact rate of biochemical response or symptomatic improvement. There is a need for large, prospective studies investigating the role of escalated-dose somatostatin analogues in the treatment of metastatic gastroenteropancreatic neuroendocrine tumours.
Authors: P Ferolla; A Faggiano; F Grimaldi; D Ferone; G Scarpelli; V Ramundo; R Severino; M C Bellucci; L M Camera; G Lombardi; G Angeletti; A Colao Journal: J Endocrinol Invest Date: 2011-07-13 Impact factor: 4.256
Authors: Matthew H Kulke; Lillian L Siu; Joel E Tepper; George Fisher; Deborah Jaffe; Daniel G Haller; Lee M Ellis; Jacqueline K Benedetti; Emily K Bergsland; Timothy J Hobday; Eric Van Cutsem; James Pingpank; Kjell Oberg; Steven J Cohen; Mitchell C Posner; James C Yao Journal: J Clin Oncol Date: 2011-01-24 Impact factor: 44.544
Authors: Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245
Authors: Eugene A Woltering; Vergilio A Salvo; Thomas M O'Dorisio; John Lyons; Gang Li; Ying Zhou; Jacky R Seward; Vay Liang W Go; Arthur I Vinik; Paris Mamikunian; Gregg Mamikunian Journal: Pancreas Date: 2008-07 Impact factor: 3.327
Authors: M di Bartolomeo; E Bajetta; R Buzzoni; L Mariani; C Carnaghi; L Somma; N Zilembo; A di Leo Journal: Cancer Date: 1996-01-15 Impact factor: 6.860
Authors: Martyn E Caplin; Marianne Pavel; Jarosław B Ćwikła; Alexandria T Phan; Markus Raderer; Eva Sedláčková; Guillaume Cadiot; Edward M Wolin; Jaume Capdevila; Lucy Wall; Guido Rindi; Alison Langley; Séverine Martinez; Joëlle Blumberg; Philippe Ruszniewski Journal: N Engl J Med Date: 2014-07-17 Impact factor: 91.245
Authors: Jonathan Ac Sterne; Miguel A Hernán; Barnaby C Reeves; Jelena Savović; Nancy D Berkman; Meera Viswanathan; David Henry; Douglas G Altman; Mohammed T Ansari; Isabelle Boutron; James R Carpenter; An-Wen Chan; Rachel Churchill; Jonathan J Deeks; Asbjørn Hróbjartsson; Jamie Kirkham; Peter Jüni; Yoon K Loke; Theresa D Pigott; Craig R Ramsay; Deborah Regidor; Hannah R Rothstein; Lakhbir Sandhu; Pasqualina L Santaguida; Holger J Schünemann; Beverly Shea; Ian Shrier; Peter Tugwell; Lucy Turner; Jeffrey C Valentine; Hugh Waddington; Elizabeth Waters; George A Wells; Penny F Whiting; Julian Pt Higgins Journal: BMJ Date: 2016-10-12
Authors: Sally K Abell; Jessie Teng; Anthony Dowling; Michael S Hofman; Richard J MacIsaac; Nirupa Sachithanandan Journal: Endocrinol Diabetes Metab Case Rep Date: 2015-01-01
Authors: Edward M Wolin; Barbara Jarzab; Barbro Eriksson; Thomas Walter; Christos Toumpanakis; Michael A Morse; Paola Tomassetti; Matthias M Weber; David R Fogelman; John Ramage; Donald Poon; Brian Gadbaw; Jiang Li; Janice L Pasieka; Abakar Mahamat; Fredrik Swahn; John Newell-Price; Wasat Mansoor; Kjell Öberg Journal: Drug Des Devel Ther Date: 2015-09-03 Impact factor: 4.162
Authors: Nicole Brighi; Francesco Panzuto; Roberta Modica; Fabio Gelsomino; Manuela Albertelli; Sara Pusceddu; Sara Massironi; Giuseppe Lamberti; Maria Rinzivillo; Antongiulio Faggiano; Andrea Spallanzani; Diego Ferone; Natalie Prinzi; Roberta Elisa Rossi; Bruno Annibale; Anna Maria Colao; Davide Campana Journal: Oncologist Date: 2019-11-06
Authors: Nicole Brighi; Francesco Panzuto; Roberta Modica; Fabio Gelsomino; Manuela Albertelli; Sara Pusceddu; Sara Massironi; Giuseppe Lamberti; Maria Rinzivillo; Antongiulio Faggiano; Andrea Spallanzani; Diego Ferone; Natalie Prinzi; Roberta Elisa Rossi; Bruno Annibale; Anna Maria Colao; Davide Campana Journal: Oncologist Date: 2019-11-06
Authors: Elsa M Ronde; Charlotte M Heidsma; Anne M Eskes; Josefine E Schopman; Elisabeth J M Nieveen van Dijkum Journal: Eur J Cancer Care (Engl) Date: 2021-08-30 Impact factor: 2.328
Authors: Elettra Merola; Andrea Michielan; Umberto Rozzanigo; Marco Erini; Sandro Sferrazza; Stefano Marcucci; Chiara Sartori; Chiara Trentin; Giovanni de Pretis; Franca Chierichetti Journal: World J Gastrointest Surg Date: 2022-02-27
Authors: Maria Isabel Del Olmo-Garcia; Stefan Prado-Wohlwend; Alexia Andres; Jose M Soriano; Pilar Bello; Juan Francisco Merino-Torres Journal: Biomedicines Date: 2021-12-01